Analysis of the drug-resistance of Pseudomonas aeruginosa and the use of antibiotics in burn wards

Chinese Journal of Burns

Volumn 27, Issue 2, 2011, Pages 109-113

  Dou, Yi ^a   Zhang, Xiong ^a   Zhang, Qin ^a   Shi, Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti bacterial agents; Burns; Drug resistance; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; LEVOFLOXACIN; SULPERAZON; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BLOOD; BURN PATIENT; FECES; HUMAN; INTRAVENOUS CATHETER; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPUTUM; STAPHYLOCOCCUS AUREUS; URINE; WOUND;

ANTI-BACTERIAL AGENTS; BURN UNITS; BURNS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79955892219     PISSN: 10092587     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1009-2587.2011.02.008     Document Type: Article

References (12)

1. Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis, 2005, 40 Suppl 2: S89-98.
2. Cizman M, Srovin T, Pokorn M, et al. Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia. J Antimicrob Chemother, 2005,55(5):758-763.
3. Mentzelopoulos SD, Pratikaki M, Platsouka E, et al. Prolonged use of carbapenems and Colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med, 2007,33(9):1524-1532. (Pubitemid 47312466)
4. Yuan Z, Ledesma KR, Singh R, et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis, 2010,201(6):889-897.
5. Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am, 2009,23(2):277-293.
6. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis, 2008,47 Suppl 1:S3-13.
7. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem, 2008,15(5):517-522.
8. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother, 2006,50(1):43-48. (Pubitemid 43042900)